Approval in Paroxysmal Nocturnal Hemoglobinuria With Pediatric IndicationByGina MauroSeptember 9th 2021The European Commission has granted an expanded approval to ravulizumab-cwvz to include children with a body weight of at least 10 kg, as well as adolescents, with paroxysmal nocturnal hemoglobinuria.